This suggests that strategies to inhibit YAP/TAZ may also help to improve immunotherapy in certain YAPon cancers, and indeed, blocking YAP/TEAD through genetic ablation or pharmacological inhibition can enhance tumor sensitivity to anti-PD-1 therapy in pre-clinical models [136]. The gene discussed is YAP1; the disease is cancer.